학술논문


EBSCO Discovery Service
발행년
-
(예 : 2010-2015)
전자자료 공정이용 안내

우리 대학 도서관에서 구독·제공하는 모든 전자자료(데이터베이스, 전자저널, 전자책 등)는 국내외 저작권법과 출판사와의 라이선스 계약에 따라 엄격하게 보호를 받고 있습니다.
전자자료의 비정상적 이용은 출판사로부터의 경고, 서비스 차단, 손해배상 청구 등 학교 전체에 심각한 불이익을 초래할 수 있으므로, 아래의 공정이용 지침을 반드시 준수해 주시기 바랍니다.

공정이용 지침
  • 전자자료는 개인의 학습·교육·연구 목적의 비영리적 사용에 한하여 이용할 수 있습니다.
  • 합리적인 수준의 다운로드 및 출력만 허용됩니다. (일반적으로 동일 PC에서 동일 출판사의 논문을 1일 30건 이하 다운로드할 것을 권장하며, 출판사별 기준에 따라 다를 수 있습니다.)
  • 출판사에서 제공한 논문의 URL을 수업 관련 웹사이트에 게재할 수 있으나, 출판사 원문 파일 자체를 복제·배포해서는 안 됩니다.
  • 본인의 ID/PW를 타인에게 제공하지 말고, 도용되지 않도록 철저히 관리해 주시기 바랍니다.
불공정 이용 사례
  • 전자적·기계적 수단(다운로딩 프로그램, 웹 크롤러, 로봇, 매크로, RPA 등)을 이용한 대량 다운로드
  • 동일 컴퓨터 또는 동일 IP에서 단시간 내 다수의 원문을 집중적으로 다운로드하거나, 전권(whole issue) 다운로드
  • 저장·출력한 자료를 타인에게 배포하거나 개인 블로그·웹하드 등에 업로드
  • 상업적·영리적 목적으로 자료를 전송·복제·활용
  • ID/PW를 타인에게 양도하거나 타인 계정을 도용하여 이용
  • EndNote, Mendeley 등 서지관리 프로그램의 Find Full Text 기능을 이용한 대량 다운로드
  • 출판사 콘텐츠를 생성형 AI 시스템에서 활용하는 행위(업로드, 개발, 학습, 프로그래밍, 개선 또는 강화 등)
위반 시 제재
  • 출판사에 의한 해당 IP 또는 기관 전체 접속 차단
  • 출판사 배상 요구 시 위반자 개인이 배상 책임 부담
'학술논문' 에서 검색결과 218건 | 목록 1~20
Academic Journal
J Clin Oncol
Grob, T, Sanders, M A, Vonk, C M, Kavelaars, F G, Rijken, M, Hanekamp, D W, Gradowska, P L, Cloos, J, Fløisand, Y, van Marwijk Kooy, M, Manz, M G, Ossenkoppele, G J, Tick, L W, Havelange, V, Löwenberg, B, Jongen-Lavrencic, M & Valk, P J M 2023, 'Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 41, no. 4, pp. 756-765. https://doi.org/10.1200/JCO.22.00715, https://doi.org/10.1200/JCO.22.00715
Journal of clinical oncology, Vol. 41, no. 4, p. 756-765 (2023)
Academic Journal
Blood
Grob, T, Al Hinai, A S A, Sanders, M A, Kavelaars, F G, Rijken, M, Gradowska, P L, Biemond, B J, Breems, D A, Maertens, J, van Marwijk Kooy, M, Pabst, T, de Weerdt, O, Ossenkoppele, G J, van de Loosdrecht, A A, Huls, G A, Cornelissen, J J, Beverloo, H B, Löwenberg, B, Jongen-Lavrencic, M & Valk, P J M 2022, 'Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome', Blood, vol. 139, no. 15, pp. 2347-2354. https://doi.org/10.1182/blood.2021014472
Academic Journal
Löwenberg, B, Pabst, T, Maertens, J, Gradowska, P, Biemond, B J, Spertini, O, Vellenga, E, Griskevicius, L, Tick, L W, Jongen-Lavrencic, M, Kooy, M V M, Vekemans, M-C, van der Velden, W J F M, Beverloo, B, Michaux, L, Graux, C, Deeren, D, Weerdt, O D, Esser, J W J V, Klein, M B S K, Gadisseur, A, Westerweel, P E, Veelken, H, Gregor, M, Silzle, T, Lammeren-Venema, D Ë V, Moors, I, Breems, D A, Hoogendoorn, M, Legdeur, M-C J C, Fischer, T, Kuball, J, Porkka, J C K, Juliusson, G, Meyer, P, Höglund, M, Gjertsen, B T, Janssen, J J W M, Huls, G, Passweg, J, Cloos, J, Valk, P J M, Elssen, C H M J V, Manz, M G, Floisand, Y & Ossenkoppele, G J 2021, 'Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: The HOVON-SAKK-132 trial', Blood, vol. 5, no. 4, pp. 1110-1121. https://doi.org/10.1182/bloodadvances.2020003855
Blood Advances, 5, 4, pp. 1110-1121
Blood advances, Vol. 5, no. 4, p. 1110-1121 (2021)
Blood advances
BLOOD ADVANCES
Academic Journal
Lugtenburg, P J, de Nully Brown, P, van der Holt, B, D'Amore, F A, Koene, H R, de Jongh, E, Fijnheer, R, van Esser, J W, Böhmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, van der Burg-de Graauw, N C, Oosterveld, M, Jie, K-S G, Larsen, T S, van der Poel, M W, Leijs, M B, Silbermann, M H, van Marwijk Kooy, M, Beker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, de Keizer, B, Arens, A I, de Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, 'Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)', Journal of Clinical Oncology, vol. 38, no. 29, 38, pp. 3377-3387. https://doi.org/10.1200/JCO.19.03418, https://doi.org/DOI: 10.1200/JCO.19.03418
Journal of Clinical Oncology, 38, 29, pp. 3377-3387
Lugtenburg, P J, De Nully Brown, P, Van der Holt, B, D'Amore, F A, Koene, H R, De Jongh, E, Fijnheer, R, Van Esser, J W, Bohmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, Van der Burg-De Graauw, N C, Oosterveld, M, Jie, K S G, Larsen, T S, Van der Poel, M W, Leijs, M B, Silbermann, M H, Van Marwijk Kooy, M, Beeker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, De Keizer, B, Arens, A I, De Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-chop with early rituximab intensification for diffuse large b-cell lymphoma : A randomized phase iii trial of the hovon and the nordic lymphoma group (hovon-84) ', Journal of Clinical Oncology, vol. 38, no. 29, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418
Lugtenburg, P J, De Nully Brown, P, Van der Holt, B, D'Amore, F A, Koene, H R, De Jongh, E, Fijnheer, R, Van Esser, J W, Bohmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, Van der Burg-De Graauw, N C, Oosterveld, M, Jie, K S G, Larsen, T S, Van der Poel, M W, Leijs, M B, Silbermann, M H, Van Marwijk Kooy, M, Beeker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, De Keizer, B, Arens, A I, De Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, 'Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma : A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)', Journal of Clinical Oncology, vol. 38, no. 29, pp. 3377-3387. https://doi.org/10.1200/JCO.19.03418
Academic Journal
Cavo, M, Gay, F, Beksac, M, Pantani, L, Petrucci, M T, Dimopoulos, M A, Dozza, L, van der Holt, B, Zweegman, S, Oliva, S, van der Velden, V H J, Zamagni, E, Palumbo, G A, Patriarca, F, Montefusco, V, Galli, M, Maisnar, V, Gamberi, B, Hansson, M, Belotti, A, Pour, L, Ypma, P, Grasso, M, Croockewit, A, Ballanti, S, Offidani, M, Vincelli, I D, Zambello, R, Liberati, A M, Andersen, N F, Broijl, A, Troia, R, Pascarella, A, Benevolo, G, Levin, M D, Bos, G, Ludwig, H, Aquino, S, Morelli, A M, Wu, K L, Boersma, R, Hajek, R, Durian, M, von dem Borne, P A, Caravita di Toritto, T, Driessen, C, Specchia, G, Waage, A, Gimsing, P, Mellqvist, U H, van Marwijk Kooy, M, Minnema, M, Mandigers, C, Cafro, A M, Palmas, A, Carvalho, S, Spencer, A, Boccadoro, M & Sonneveld, P 2020, 'Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95) : a multicentre, randomised, open-label, phase 3 study', The Lancet Haematology, vol. 7, no. 6, pp. e456-e468. https://doi.org/10.1016/S2352-3026(20)30099-5
Lancet Haematology, 7, 6, pp. E456-E468
Cavo, M, Gay, F, Beksac, M, Pantani, L, Petrucci, M T, Dimopoulos, M A, Dozza, L, van der Holt, B, Zweegman, S, Oliva, S, van der Velden, V H J, Zamagni, E, Palumbo, G A, Patriarca, F, Montefusco, V, Galli, M, Maisnar, V, Gamberi, B, Hansson, M, Belotti, A, Pour, L, Ypma, P, Grasso, M, Croockewit, A, Ballanti, S, Offidani, M, Vincelli, I D, Zambello, R, Liberati, A M, Andersen, N F, Broijl, A, Troia, R, Pascarella, A, Benevolo, G, Levin, M-D, Bos, G, Ludwig, H, Aquino, S, Morelli, A M, Wu, K L, Boersma, R, Hajek, R, Durian, M, Borne, P A V D, di Toritto, T C, Zander, T, Specchia, G, Waage, A, Gimsing, P, Mellqvist, U-H, Kooy, M V M, Minnema, M, Mandigers, C, Cafro, A M, Palmas, A, Carvalho, S, Spencer, A, Boccadoro, M & Sonneveld, P 2020, 'Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95) : a multicentre, randomised, open-label, phase 3 study', The Lancet Haematology, vol. 7, no. 6, pp. E456-E468. https://doi.org/10.1016/S2352-3026(20)30099-5
Academic Journal
Löwenberg, B, Pabst, T, Maertens, J, Van Norden, Y, Biemond, B J, Schouten, H C, Spertini, O, Vellenga, E, Graux, C, Havelange, V, De Greef, G E, De Weerdt, O, Legdeur, M C J C, Kuball, J, Van Marwijk Kooy, M, Gjertsen, B T, Jongen-Lavrencic, M, Van De Loosdrecht, A A, Van Lammeren-Venema, D, Hodossy, B, Breems, D A, Chalandon, Y, Passweg, J, Valk, P J M, Manz, M G & Ossenkoppele, G J 2017, 'Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML', Blood, vol. 129, no. 12, pp. 1636-1645. https://doi.org/10.1182/blood-2016-10-740613
Blood, Vol. 129, No 12 (2017) pp. 1636-1645
Academic Journal
Sonneveld, P, Asselbergs, E, Zweegman, S, van der Holt, B, Kersten, M J, Vellenga, E, van Marwijk-Kooy, M, Broyl, A, de Weerdt, O, Lonergan, S, Palumbo, A & Lokhorst, H M 2015, 'Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma', Blood, vol. 125, no. 3, pp. 449-456. https://doi.org/10.1182/blood-2014-05-576256
Academic Journal
Cornelissen, J J, van der Holt, B, Verhoef, G E G, van 't Veer, M B, van Oers, M H J, Schouten, H C, Ossenkoppele, G J, Sonneveld, P, Maertens, J, Kooy, M V, Schaafsma, M R, Wijermans, P W, Biesma, D H, Wittebol, S, Voogt, P J, Baars, J W, Zachee, P, Verdonck, L F, Lowenberg, B & Dekker, A W 2009, 'Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison', Blood, vol. 113, no. 6, pp. 1375-1382. https://doi.org/10.1182/blood-2008-07-168625
Academic Journal
Haematologica, Vol 99, Iss 1 (2014)
Scheid, C, Sonneveld, P, Schmidt-Wolf, I G H, van der Holt, B, el Jarari, L, Bertsch, U, Salwender, H, Zweegman, S, Blau, I W, Vellenga, E, Weisel, K, Pfreundschuh, M, Jie, K S, Neben, K, van der Velde, H, Duehrsen, U, Schaafsma, M R, Lindemann, W, Kersten, M J, Peter, N, Hanel, M, Croockewit, S, Martin, H, Wittebol, S, Bos, G M J, van Marwijk-Kooy, M, Wijermans, P, Goldschmidt, H & Lokhorst, H M 2014, 'Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial', Haematologica, vol. 99, no. 1, pp. 148-154. https://doi.org/10.3324/haematol.2013.087585
Haematologica, 99, 1, pp. 148-54
Academic Journal
Deenik, W, van der Holt, B, Verhoef, GE, Smit, W M, Kersten, M J, Kluin-Nelemans, H C, Verdonck, L F, Ferrant, A, Schattenberg, A V, Janssen, J J W M, Sonneveld, P, van Marwijk, K M, Wittebol, S, Willemze, R, Wijermans, P W, Westveer, PH, Beverloo, HB, van der Valk, P, Lowenberg, B, Ossenkoppele, G J & Cornelissen, J J 2008, 'Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia', Blood, vol. 111, no. 5, pp. 2581-2588. https://doi.org/10.1182/blood-2007-08-107482
Blood, 111, 5, pp. 2581-2588
Academic Journal
Haematologica, Vol 93, Iss 1 (2008)
Lokhorst, H M, Schmidt-Wolf, I, Van Der Holt, P S, Martin, H, Barge, R, Bertsch, U, Schlenzka, J, Bos, G M J, Croockewit, S, Zweegman, S, Breitkreuz, I, Joosten, P, Scheid, C, Van Marwijk-Kooy, M, Salwender, H J, Van Oers, M H J, Schaafsma, R, Naumann, R, Sinnige, H, Blau, I, Verhoef, G, De Weerdt, O, Wijermans, P, Wittebol, S, Duersen, U, Vellenga, E & Goldschmidt, H 2008, 'Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma', Haematologica, vol. 93, no. 1, pp. 124-127. https://doi.org/10.3324/haematol.11644
Haematologica, 93, 1, pp. 124-7
검색 결과 제한하기
제한된 항목
[검색어] van Marwijk, Marinus
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어